A5033486865- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Psoriasis: Treatment and Pathogenesis
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Bone and Joint Diseases
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral Infections and Immunology Research
- Musculoskeletal synovial abnormalities and treatments
- Health Systems, Economic Evaluations, Quality of Life
- Immunodeficiency and Autoimmune Disorders
- HER2/EGFR in Cancer Research
- Hepatitis C virus research
- Cell Adhesion Molecules Research
- Clinical practice guidelines implementation
- Oral microbiology and periodontitis research
- Systemic Sclerosis and Related Diseases
- Immune Cell Function and Interaction
- Sarcoidosis and Beryllium Toxicity Research
- Peripheral Neuropathies and Disorders
Inserm
2013-2024
Université de Bretagne Occidentale
2024
Université Toulouse III - Paul Sabatier
2013-2023
Hôpital Paule de Viguier
2015-2022
Centre Hospitalier Universitaire de Toulouse
2013-2022
Université de Toulouse
2007-2022
Hôpital de La Grave
2010-2022
Institut Toulousain des Maladies Infectieuses et Inflammatoires
2021
Hôpital Purpan
2012-2021
Centre National de la Recherche Scientifique
2012-2021
The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy.499 inadequate response one or more TNF antagonists were randomly assigned receive 8 mg/kg 4 tocilizumab placebo (control) intravenously every weeks stable methotrexate for 24 weeks. ACR20 responses, secondary endpoints assessed.ACR20 was achieved at by 50.0%, 30.4% 10.1%...
The risk of severe infection is a crucial factor in the assessment short-term risk:benefit ratio biologic drugs rheumatoid arthritis (RA). There no increase infections RA patients treated with rituximab (RTX) controlled trials, but this has not yet been assessed daily practice. We undertook study to investigate occurrence and factors for off-trial using data from AutoImmunity Rituximab (AIR) registry.The AIR registry was set up by French Society Rheumatology. charts were reviewed.Of enrolled...
<h3>Objectives</h3> This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations tocilizumab in patients with rheumatoid arthritis an inadequate response to disease-modifying antirheumatic drugs (DMARD). <h3>Methods</h3> Patients (n=1262) were randomly assigned receive tocilizumab-SC 162 mg weekly+placebo-IV every 4 weeks or tocilizumab-IV 8 mg/kg weeks+placebo-SC weekly combination traditional DMARD. The primary outcome was demonstrate...
To determine prognostic factors of radiologic damage and progression in early rheumatoid arthritis (RA).A cohort 191 patients with RA whose disease duration was shorter than 1 year were prospectively followed up for 3 years. Radiologic scores (as determined by Sharp's method, modified van der Heijde) used as outcome measures. Numerous baseline clinical, laboratory, genetic, radiographic data obtained.The change the total score over years a mean +/- SD increase 6.1 6.2. observed 71 172 whom...
<h3>OBJECTIVES</h3> To investigate the potential clinical benefit of a combination therapy. <h3>METHODS</h3> 205 patients fulfilling ACR criteria for rheumatoid arthritis (RA), not treated with disease modifying anti-rheumatoid drugs previously, an early (⩽1 year duration), active (Disease Activity Score (DAS) > 3.0), factor and/or HLA DR 1/4 positive were randomised between sulphasalazine (SASP) 2000 (maximum 3000) mg daily (n = 68), or methotrexate (MTX) 7.5 15) weekly 69) (SASP + MTX)...
Objective To test if interleukin-1β (IL-1β), IL-1 receptor antagonist (IL-1Ra), IL-4, or IL-10 gene polymorphisms could be used as markers of susceptibility severity in rheumatoid arthritis (RA). Methods The study included 108 patients with early RA followed up for 2 years and 128 healthy controls. From genomic DNA, 6 genes IL-1β, IL-1Ra, IL-10, IL-4 were typed. Allelic frequencies carriage rates compared between controls, erosive nonerosive RA, without sustained remission. Results RP1...
IgG anti-filaggrin autoantibodies (AFA) are the most specific serological markers of rheumatoid arthritis (RA). They include so-called 'anti-keratin antibodies' (AKA) and anti-perinuclear factor (APF), recognize human epidermal filaggrin other (pro)filaggrin-related proteins various epithelial tissues. In this study we demonstrate that AFA produced in synovial joints. 31 RA patients, levels were assayed at equal concentrations paired fluids (SF) sera. titre-like values determined by indirect...
Abstract Objective The Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) is a 3‐year, double‐blind, multicenter study evaluating the efficacy safety etanercept, methotrexate, combination etanercept plus methotrexate in patients active rheumatoid arthritis (RA). results after 1 2 years have been previously reported. Here we provide 3‐year clinical radiographic outcomes RA. Methods In this randomized, TEMPO study, 682 received 25 mg twice weekly, ≤20 or...
Objectives Very limited data are available regarding the efficacy of abatacept (ABA) in real life. The aims this study were to determine ABA rheumatoid arthritis and predicting factors common practice. Methods Orencia Rheumatoid Arthritis” (ORA) prospective registry, promoted by French Society Rheumatology, has included 1003 patients with RA. Results 773 had already fulfilled 6-month follow-up visit. Only 21.3% would have inclusion criteria used pivotal controlled trials. European League...
This article reports the latest recommendations of French Society for Rheumatology (SFR) regarding management rheumatoid arthritis (RA). New were developed by hospital- and community-based rheumatologists having extensive experience with RA a patient self-help organization representative. They rest on recently issued EULAR literature review. Points emphasized in 15 include need to share treatment decisions between rheumatologist patient, acquisition patients self-management skills, remission...
To evaluate the long-term efficacy and safety of subcutaneous (SC) tocilizumab (TCZ) versus intravenous (IV) TCZ, including switching formulations, in patients with rheumatoid arthritis (RA) inadequate response to disease-modifying antirheumatic drugs (DMARDs).Patients (n=1262) were randomised 1:1 receive TCZ-SC 162 mg weekly (qw)+placebo-IV every four weeks (q4w) or TCZ-IV 8 mg/kg q4w+placebo-SC qw combination DMARD(s). After a 24-week double-blind period, receiving re-randomised 11:1...
Oxidative stress plays an important role in the induction of T lymphocyte hyporesponsiveness observed several human pathologies including cancer, rheumatoid arthritis, leprosy, and AIDS. To investigate molecular basis oxidative stress-induced cell hyporesponsiveness, we have developed vitro system which lymphocytes are rendered hyporesponsive by co-culture with oxygen radical-producing activated neutrophils. We a direct correlation between level induced concentration reactive species...
Abstract Endothelial cells play a central role in chronic inflammation: for example, they express adhesion molecules and present chemokines leading to enhanced leukocyte recruitment into tissues. Numerous markers of endothelial have been reported but there has lack comparative data on their specificity. The study compared the specificity seven cell rheumatoid synovium colon patients with Crohn's disease. These were: sulphated epitope MECA‐79, Duffy antigen receptor (DARC), von Willebrand...